Natrol launches vitamin supplement
CHATSWORTH, Calif. Natrol on Thursday launched Fish Oil + Vitamin D3, a combination of nutrients for overall health and immunity. The supplement is formulated as a softgel to be taken once daily at an average suggested retail price of $16.99.
The company cited recent scientific studies that have shown vitamin D3 — the vitamin that the body manufactures from sunlight — to be beneficial for aiding overall health, including bone health, immunity support and cellular protection in both men and women, and especially for middle-age and older adults, as the genesis for combining the two ingredients.
Commonly known for their heart health and bone health benefits, fish oil (omega-3 fats) and vitamin D have recently been studied for their cellular activity and abilities to promote breast health, colon health and prostate health, Natrol added. At the cellular level, research shows that omega-3 fats are the building blocks for cellular membranes.
Luckianow joins Greenwood Group
BUFFALO, N.Y. The Greenwood Group on Wednesday announced the addition of Neil Luckianow to its team.
“[Luckianow’s] expertise in trade marketing and sales will be a great asset to our organization and our clients. We’re excited to have him on board,” stated Patrick O’Leary, president of Greenwood Group.
Luckianow has 25 years of experience and is a recognized expert in trade marketing, trade relations and sales management. His achievements include designing retail sales and marketing strategies that reverse market-share slides and help clients bring products successfully from inception to full commercialization, the Greenwood Group stated.
FDA approves Dr. Reddy’s heartburn generic
HYDERABAD, India The Food and Drug Administration has approved a generic version of the OTC formulation of AstraZeneca’s Prilosec.
Indian generic drug maker Dr. Reddy’s Labs announced Tuesday the approval of its omeprazole magnesium in the 20.6 mg strength, which is used to treat heartburn.
The company said it expects to begin shipment of the drug in second quarter of its fiscal year 2010.